The management of moderate to severe anemia in patients with myelofibrosis скачать в хорошем качестве

The management of moderate to severe anemia in patients with myelofibrosis

Mary Frances McMullin, MD, Queen's University, Belfast, UK, provides insight into managing moderate to severe anemia in patients with myelofibrosis (MF). It is crucial that clinicians investigate the cause of the anemia and measure erythropoietin levels prior to initiating treatment. The anemia can then be managed with erythropoiesis-stimulating agents (ESAs) or several other agents, such as danazol. Prof. McMullin also emphasizes that ruxolitinib, the frontline treatment option for MF, may decrease hemoglobin levels and worsen anemia; therefore, the novel agent momelotinib will likely become the first choice when treating patients. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.